| AD | Alzheimer’s Disease |
| ANCOVA | Analysis of Covariance |
| AUC | Area Under the Curve |
| AUPRC | Area Under the Precision–Recall Curve |
| AT(N) | Amyloid/Tau/Neurodegeneration Framework |
| Aβ42 | Amyloid-Beta 42 |
| BIOMARKAPD | Biomarkers for Alzheimer’s Disease |
| CDT | Clock Drawing Test |
| CI | Confidence Interval |
| CPM-47 | Raven’s Colored Progressive Matrices (47 items) |
| CSF | Cerebrospinal Fluid |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition |
| ELISA | Enzyme-Linked Immunosorbent Assay |
| FAB | Frontal Assessment Battery |
| FDR | False Discovery Rate |
| FDG-PET | Fluorodeoxyglucose Positron Emission Tomography |
| MCI | Mild Cognitive Impairment |
| MMSE | Mini-Mental State Examination |
| MoCA | Montreal Cognitive Assessment |
| MRI | Magnetic Resonance Imaging |
| NfL | Neurofilament Light |
| OR | Odds Ratio |
| PET | Positron Emission Tomography |
| pTau | Phosphorylated Tau |
| RAVLT | Rey Auditory Verbal Learning Test |
| ROC | Receiver Operating Characteristic |
| SD | Standard Deviation |
| SNAP | Suspected Non-Alzheimer’s Pathophysiology |
| tTau | Total Tau |
| TMT-A/B | Trail Making Test Parts A and B |